<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275193</url>
  </required_header>
  <id_info>
    <org_study_id>Zishenqing</org_study_id>
    <nct_id>NCT04275193</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>The Safety and Efficacy of the Traditional Chinese Medicine Zishenqing in Subjects With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of the traditional chinese medicine Zishenqing&#xD;
      in the treatment of active systemic lupus erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a multicenter, randomized, double-blind, placebo parallel controlled&#xD;
      clinical trial with a course of 12 weeks.&#xD;
&#xD;
        1. Multicenter: During the study period, it will be decided whether to increase the&#xD;
           improvement progress of the research unit according to whether it will be difficult to&#xD;
           join the group and the overall progress, so as to complete the clinical study on time in&#xD;
           accordance with the research plan.&#xD;
&#xD;
        2. Random scheme: In this study, a dynamic random variance minimization random scheme will&#xD;
           be adopted. Considering the two influencing factors of SLEDAI score and complement&#xD;
           level, the DAS for Interactive Web Response System(IWRS) will be used to calculate and&#xD;
           distribute random numbers and dispensing drugs.&#xD;
&#xD;
        3. Control drug: Placebo will be used as control in this trial.&#xD;
&#xD;
        4. Blind method: The Zishenqing simulator will be prepared by double-blind design, the&#xD;
           dosage form, appearance, size, color and smell will be consistent with the experimental&#xD;
           drug, and the test process will be in a double-blind state.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lupus Quality of Life (LupusQoL)</measure>
    <time_frame>12weeks</time_frame>
    <description>Self reported the quality of life in patients with systemic lupus erythematosus.LupusQoL is made up of five parts((physical health, pain, planning, emotional health, and fatigue) and has a total of 34 questions.Each question is scored0-4,yielding a total between 0 and 136.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The 36-item shot form health survey(SF-36)</measure>
    <time_frame>12weeks</time_frame>
    <description>As a concise health questionnaire, SF-36 comprehensively summarizes the quality of life of the subjects from eight aspects: physiological function, physiological function, physical pain, general health status, energy, social function, emotional function and mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic lupus erythematosus disease activity index(SLEDAI)</measure>
    <time_frame>12weeks</time_frame>
    <description>SLEDAI scores are used to determine the activity of SLE.SLEDAI consists of 24 clinical and laboratory projects with different weights（0:no activity;1-5:mild activity;6-10:moderate activity;11-19:severe activity;≥20:extremely severe activity).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Zishenqing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zishenqing</intervention_name>
    <description>Zishenqing Granule</description>
    <arm_group_label>Zishenqing</arm_group_label>
    <other_name>Zishenqingqi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Granule manufactured to mimic Zishenqing(containing 10% composition)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo(for Zishenqing)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who qualify for the diagnosis of systemic lupus erythematosus according to&#xD;
             the American college of rheumatology's 1997 revised classification criteria for&#xD;
             systemic lupus erythematosus;&#xD;
&#xD;
          2. For inpatient or out-patient with good compliance, sign the informed consent before&#xD;
             the test;&#xD;
&#xD;
          3. Sledai score during screening period≤10;&#xD;
&#xD;
          4. Maintain a stable standard treatment regimen for at least 30 days before the first day&#xD;
             (that is, the date of administration of the intervention drug). Standard treatment&#xD;
             regimens refer to the stable use of any of the following (alone or in combination):&#xD;
             corticosteroids, hydroxychloroquine, non-steroidal anti-inflammatory drugs, other&#xD;
             immunosuppressants or immunomodulators (including azathioprine, mycophenolate ester,&#xD;
             cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe lupus nephritis requiring hemodialysis or high-dose glucocorticoid treatment in&#xD;
             the last 2 months;&#xD;
&#xD;
          2. Central nervous system diseases (including epilepsy, psychosis, organic encephalopathy&#xD;
             syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis)&#xD;
             caused by SLE or non-SLE in the last 2 months;&#xD;
&#xD;
          3. Patients with severe heart, liver and kidney diseases and disease history of important&#xD;
             organs, blood and endocrine system;&#xD;
&#xD;
             Evaluation criteria of severity:&#xD;
&#xD;
               1. Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST)≥3 times the&#xD;
                  upper limit of normal;&#xD;
&#xD;
               2. Glomerular filtration rate(GFR)&lt;30ml/min;&#xD;
&#xD;
               3. White Blood Cell(WBC)&lt;2.0×10^9/l;&#xD;
&#xD;
               4. Platelet(PLT)&lt;50×10^9/l;&#xD;
&#xD;
          4. Immunodeficiency, uncontrolled infection and active or recurrent peptic ulcer;&#xD;
&#xD;
          5. Pregnant and lactating women;&#xD;
&#xD;
          6. Anaphylaxis: allergic to traditional Chinese medicine;&#xD;
&#xD;
          7. The investigator considered it inappropriate to participate in this study;&#xD;
&#xD;
          8. Participate in other clinical trials during the screening period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangjing Lv, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huanru Qu, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhujing Zhu, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruru Guo, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhongping Xu, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianchun Mao, Master</last_name>
    <phone>+8618917763231</phone>
    <email>mjczyczx@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhujing Zhu, Ph.D</last_name>
    <phone>+8613816914874</phone>
    <email>zzj01@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianchun Mao, master</last_name>
      <phone>86-18917763231</phone>
      <email>mjcct2018@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>maojianchun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

